Slingshot members are tracking this event:

Keryx (KERX) Announces Phase III Results Evaluating Auryxia for the Treatment of Iron Deficiency Anemia in Patients With Stage 3-5 Non-Dialysis-Dependent Chronic Kidney Disease

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 29, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase Iii Results, Stage 3-5, Non-dialysis-dependent, Chronic Kidney Disease, Oral Iron-based Treatment, Iron Deficiency Anemia, Ferric Citrate